Comment on: Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high‐risk first relapse B‐cell precursor acute lymphoblastic leukemia

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2023-01, Vol.70 (1), p.e29874-n/a
Main Authors: Srinivasan, Shyam, Roy Moulik, Nirmalya, Dhamne, Chetan
Format: Article
Language:English
Subjects:
Acute lymphoblastic leukemia
Antibodies, Bispecific - therapeutic use
Antineoplastic Agents - therapeutic use
Child
Hematology
Humans
Lymphatic leukemia
Monoclonal antibodies
Neoplasm, Residual - drug therapy
Oncology
Pediatrics
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Prognosis
Recurrence
Targeted cancer therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.29874